Aktie A2AFC9 CEN BIOTECH, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen CEN Biotech, Inc.

Aktien

A2AFC9

CA15130L1040

CENBF

Markt geschlossen - OTC Markets
Andere Börsenplätze
 17:49:14 29.04.2024 		% 5 Tage % 1. Jan.
0,00738 USD +138,06 % Intraday Chart für CEN Biotech, Inc. +138,71 % +146,67 %
2023 CEN Biotech, Inc. gibt den Rücktritt von Lawrence Lehoux als Mitglied des Vorstands und Chief Technology Officer bekannt CI
2022 CEN Biotech, Inc. berichtet über die Ergebnisse für das dritte Quartal und die ersten neun Monate bis zum 30. September 2022 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
CEN BIOTECH INC : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
CEN Biotech, Inc. Announces Resignation of Lawrence Lehoux as a Member of the Board and Chief Technology Officer
NOTE 2 - GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS
CEN Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CEN BIOTECH INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
CEN BIOTECH INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
CEN BIOTECH INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
NOTE 2 - GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS
CEN Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CEN BIOTECH INC : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
CEN BIOTECH INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
CEN BIOTECH INC : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
CEN Biotech, Inc. announced that it has received $0.07 million in funding from 1800 Diagonal Lending, LLC
NOTE 2 - GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS
CEN Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CEN BIOTECH INC : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)
CEN BIOTECH INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
CEN Biotech, Inc. Announces Changes to Its Board
CEN BIOTECH INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
CEN Biotech, Inc. Announces Management Changes
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2AFC9 Aktie
  4. Nachrichten CEN Biotech, Inc.
  5. Andere Sprachen
: